Description: Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its iSPERSE technology. The company's proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease and other treatments. Pulmatrix, Inc. is based in Lexington, Massachusetts.
Home Page: www.pulmatrix.com
PULM Technical Analysis
99 Hayden Avenue
Lexington,
MA
02421
United States
Phone:
781 357 2333
Officers
| Name | Title |
|---|---|
| Mr. Teofilo David Raad MBA | Pres, CEO & Director |
| Dr. Alexander M. Klibanov Ph.D. | Founder |
| Mr. Peter Ludlum CMA, MBA | Interim CFO and Principal Accounting & Financial Officer |
| Dr. Aidan Curran Ph.D. | VP of Research & Scientific Affairs |
| Dr. Margaret M. Wasilewski M.D. | Chief Medical Officer |
| Mr. David J. Maki J.D. | Advisor |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3832 |
| Price-to-Sales TTM: | 2.7564 |
| IPO Date: | 2014-03-21 |
| Fiscal Year End: | December |
| Full Time Employees: | 24 |